Skip to main content

Together we are beating cancer

Donate now

Cancer News

The latest news, analysis and opinion from Cancer Research UK

Targeted therapies

Showing 12 out of 73 results
A graphic showing analysis from a genomic test.
  • Policy & Insight
  • Health & Medicine
  • Science & Technology

The story of genomics - and our plan for its next chapter

Genomics is taking us from a ‘one size fits all’ approach to cancer care to one that's much more personalised. But that change is happening quickly, and the health system is struggling to keep up. Here's our plan for making sure that genomics benefits the whole of the UK. Genomics is taking us from a ‘one size fits all’ approach to cancer care to one that's much more personalised. But that change is happening quickly, and the health system is struggling to keep up. Here's our plan for making sure that genomics benefits the whole of the UK.

by Emily Eagles, Tim Gunn | In depth | 7 November 2024

7 November 2024

Lina speaks to Dr Hugo De La Pena who is looking at cancer scans on a computer screen

Lina tells the story of how a newly available targeted drug helped slow down the growth of faulty BRCA-driven cancer in her body, giving her more time to spend with her loved ones. Lina tells the story of how a newly available targeted drug helped slow down the growth of faulty BRCA-driven cancer in her body, giving her more time to spend with her loved ones.

by Elisa Mitchell, Amy Warnock | Personal stories | 28 October 2024

28 October 2024

Cancer Research UK scientists in the lab

NHS England will offer the newly-approved dabrafenib plus trametinib combination to children and young people whose gliomas are being driven by a specific genetic mutation. NHS England will offer the newly-approved dabrafenib plus trametinib combination to children and young people whose gliomas are being driven by a specific genetic mutation.

by Tim Gunn | News | 13 June 2024

13 June 2024

Two cancer researchers looking at a cell image on screen

Each cancer is as unique as the person it affects. By studying patient data, we can target our treatments to people's specific needs. Each cancer is as unique as the person it affects. By studying patient data, we can target our treatments to people's specific needs.

by Cancer Research UK | In depth | 21 November 2023

21 November 2023

A prostate cancer cell.

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

by Jacob Smith | News | 13 September 2022

13 September 2022

3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer. 3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer.

by Harry Jenkins | News | 19 January 2022

19 January 2022

Breast cancer screening

Cancer Research UK-funded scientists are using innovative techniques to understand how resistance to a targeted cancer drug is unfolding. Cancer Research UK-funded scientists are using innovative techniques to understand how resistance to a targeted cancer drug is unfolding.

by Lilly Matson | Analysis | 10 January 2022

10 January 2022

Lung cancer cell

More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence. More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence.

by Harry Jenkins | News | 1 December 2021

1 December 2021

Lung cancer cells

Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected. Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected.

by Harry Jenkins | News | 11 November 2021

11 November 2021